IL6 and cancer: We found that (1) the presence of serum IL-6 correlated strongly with survival in patients bearing chemotherapy-resistant metastatic lung cancer; (2) patients with serum IL-6 levels ≥21 pg/mL were predicted to have shorter survival times; (3) MR16-1 had the beneficial effect of ameliorating cancer cachexia and survival.